Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
== Excavation and preparation == Usually the first evidence of fossil dinosaur eggs to be discovered are shell fragments that have eroded away from the original eggs and been transported downhill by the elements. If the source eggs can be found the area must be examined for more unexposed eggs. If the paleontologists are fortunate enough to have found a nest, the number and arrangement of the eggs must be estimated. Excavation must proceed to significant depth since many dinosaur nests include multiple layers of eggs. As the underside of the nest is excavated, it would be covered by material like newspaper, tin foil, or tissue. Afterwards, the entire block is covered in multiple layers of plaster-soaked strips of burlap. When the plaster is dried, the block is undercut the rest of the way and turned over. The fine work of cleaning the egg fossils is performed in a laboratory. Preparation usually begins from the underside of the block, which tends to be the best preserved. Because of their fragility, cleaning fossil eggs requires patience and skill. Scientists use delicate instruments like dental picks, needles, small pneumatic engraving tools, and X-Acto knives. Scientists must determine at what point to stop cleaning based on their own criteria. If eggs are fully extracted they can be more fully studied individually at the cost of information regarding the spatial relationships between eggs or if the eggs had hatched.
In the first step shown, an aldehyde derived from phenylalanine is treated with zinc dust in the presence of vanadium(III) chloride. This results in a pinacol coupling reaction which dimerizes the material to provide an intermediate which is converted to its epoxide and then reduced to (2S,3S,5S)-2,5-diamino-1,6-diphenylhexan-3-ol. Importantly, this retains the absolute stereochemistry of the amino acid precursor. The diamine is then treated sequentially with two thiazole derivatives, each linked by an amide bond, to provide ritonavir.
=== Worldwide prevalences === BED is not something only to be found in Western countries. Evidence of increasing eating disorder prevalence has been observed in "non-Western countries and among ethnic minorities". Though the research on binge eating disorders tends to be concentrated in North America, the disorder occurs across cultures. Increasing globalization has influenced the prevalence of eating disorders outside of the West. In the US, BED is present in 0.8% of male adults and 1.6% of female adults in a given year. The prevalence of BED is lower in Nordic countries compared to Europe in a study that included Finland, Sweden, Norway, and Iceland. The point prevalence ranged from 0.4 to 1.5 percent and the lifetime prevalence ranged from 0.7 to 5.8 percent for BED in women. In a study that included Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela, the point prevalence for BED was 3.53 percent. Therefore, this particular study found that the prevalence for BED is higher in these Latin American countries compared to Western countries. The prevalence of BED in Europe ranges from <1 to 4 percent.
^ Pesek, J. J.; Matyska, M. T.; Prabhakaran, S. J. (2005). "Synthesis and characterization of chemically bonded stationary phases on hydride surfaces by hydrosilation of alkynes and dienes". Journal of Separation Science. 28 (18): 2437–43. doi:10.1002/jssc.200500249. PMID 16405172. ^ Pesek, J. J.; Matyska, M. T.; Gangakhedkar, S.; Siddiq, R. (2006). "Synthesis and HPLC evaluation of carboxylic acid phases on a hydride surface". Journal of Separation Science. 29 (6): 872–80. doi:10.1002/jssc.200500433. PMID 16830499. ^ Hemström, P.; Irgum, K. (2006). "Hydrophilic interaction chromatography". Journal of Separation Science. 29 (12): 1784–821. doi:10.1002/jssc.200600199. PMID 16970185. ^ C. Kulsing, Y. Nolvachai, P.J. Marriott, R.I. Boysen, M.T. Matyska, J.J. Pesek, M.T.W. Hearn, J. Phys. Chem B, 119 (2015) 3063-3069. ^ J. Soukup, P. Janas, P. Jandera, J. Chromatogr. A, 1286 (2013) 111-118
=== Personal life === Flory was born in Sterling, Illinois, on June 19, 1910 to Ezra Flory and Martha Brumbaugh. His father worked as a clergyman-educator, and his mother was a school teacher. His ancestors were German Huguenots, who traced their roots back to Alsace. He first gained an interest in science from Carl W Holl, who was a chemistry professor at Manchester College. In 1936, he married Emily Catherine Tabor. They had three children together: Susan Springer, Melinda Groom and Paul John Flory, Jr. His first position was at DuPont with Wallace Carothers. He was posthumously inducted into the Alpha Chi Sigma Hall of Fame in 2002. Flory died on September 9, 1985, following a heart attack. His wife Emily died in 2006 aged 94.
Sources: en.wikipedia.org
In pharmacology, inorganic bromide compounds, especially potassium bromide, were frequently used as general sedatives in the 19th and early 20th century. Porsche in 1828 used KBr for scrofula. Otto Graf in a 1842 thesis reported that he became impotent while taking 1.8 g/day for two weeks as a self-experiment, and recovered sexual function upon ending the intake. Huette in 1850 reported that it caused impotence and loss of libido. Charles Locock in 1856 administered to women with "hysterical epilepsy", whose symptoms included masturbation. Locock theorized that masturbation caused epilepsy in these cases, and adiminstered KBr based on its anaphrodisiac effect. It caused a remission of epilepsy and masturbation. Locock did not understand KBr as an anticonvulsant in its own right. Subsequent research in the 1860s established KBr as generally effective for epilepsy, not just "hysterical" epilepsy, and it came into widespread use. In 1901, the Hospital for the Palsied and Epileptic in London was buying ~2 ton/year of KBr. Bromides also were recommended for insomnia, palpitations, and general neuroses, until barbituates supplanted them around 1930. It remained the only effective anticonvulsant, until the discovery of phenobarbital in 1912. Bromides in the form of simple salts are still used as anticonvulsants in both veterinary and human medicine, although the latter use varies from country to country. For example, the U.S.
=== Lethal use === Pentobarbital has been publicized as a suicide method by assisted suicide advocacy groups, in particular Exit International. Around 2008, suicide tourists were traveling to Mexico in order to purchase pentobarbital from veterinary pharmacies, a means that is no longer possible owing to tighter controls. Around 2025, prosecutions for its illegal distribution to persons seeking to end their lives have occurred in Australia, France, and the United States.
=== Industry research funding === A 2025 review found that nutritional studies on red meat consumption funded by the meat industry reported favorable (20.7%) or neutral (79.3%) cardiovascular outcomes for red meat intake. This was in opposition to independent studies that reported unfavourable (73.3%) or neutral (26.7%) cardiovascular outcomes. The review concluded that "most studies without conflicts of interest with the red meat industry suggested an unfavorable effect of unprocessed red meat consumption on risk factors for cardiovascular disease".
== Pharmacology == Experiments on former addicts indicated it was quite addictive and in high doses, compared to other opioids, may have increased abuse potential in former and current opioid addicts. While some effort was first suggested for drafting of a resolution urging governments to stop manufacture and use of ketobemidone, this result was not in agreement with clinical observations, and another study in 1958 did not find it more addictive than morphine. That study noticed that while for morphine the dose for euphoria is the same as that for analgesia, for ketobemidone the analgesic dose was well below the euphoric dose. Thus, even compared to morphine, ketobemidone may be much more effective without causing significant euphoria and thus having a lower risk of addiction under the supervision of a qualified clinician. Ketobemidone is mostly used in the Scandinavian countries, with Denmark topping the statistics. Analgesia after 5-10 mg orally or 5–7.5 mg intravenously lasts 3–5 hours. Ketobemidone is also available in preparations with a spasmolytic, which can improve the analgesia.
Topical analgesia is generally recommended to avoid systemic side-effects. Painful joints, for example, may be treated with an ibuprofen- or diclofenac-containing gel (The labeling for topical diclofenac has been updated to warn about drug-induced hepatotoxicity.); capsaicin also is used topically. Lidocaine, an anesthetic, and steroids may be injected into joints for longer-term pain relief. Lidocaine is also used for painful mouth sores and to numb areas for dental work and minor medical procedures. In February 2007 the FDA notified consumers and healthcare professionals of the potential hazards of topical anesthetics entering the bloodstream when applied in large doses to the skin without medical supervision. These topical anesthetics contain anesthetic drugs such as lidocaine, tetracaine, benzocaine, and prilocaine in a cream, ointment, or gel.
Sources: en.wikipedia.org
Heavy water reactors and some graphite moderated reactors can use natural uranium, but light water reactors must use low enriched uranium because of the higher neutron absorption of light water. Uranium enrichment removes some of the uranium-238 and increases the proportion of uranium-235. Highly enriched uranium (HEU), which contains an even greater proportion of uranium-235, is sometimes used in the reactors of nuclear submarines, research reactors and nuclear weapons.
=== Oxidation === The oxidation of isatin using hydrogen peroxide (Baeyer–Villiger oxidation) or chromic anhydride yields isatoic anhydride, a compound widely used either in herbicide products and in medicinal chemistry. The use of peroxydisulfuric acid gives rise to 1,4‑benzoxazine compounds.
On November 19, 2019, a lawsuit was filed by a vegan from Atlanta, Georgia, against Burger King for allegedly failing to clearly disclose that Impossible Whopper burgers were heated on the same grill as their beef burgers. The lawsuit was dismissed. On March 28, 2022, a lawsuit was filed against Burger King, alleging the fast food chain falsely advertised the Whopper to "look about 35% bigger in its advertising than it is in reality". On May 5, 2025, Federal Judge Roy Altman allowed the case to proceed, stating the claims may reasonably suggest consumers were misled and that Florida law permits such misrepresentation suits without a special relationship. Burger King argued that differences between ads and actual burgers are typical of handmade food and standard marketing practices.
=== Mood disorders === In the case of mood disorders, specifically bipolar disorder, it is hypothesized that N-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), S-adenosylmethionine (SAMe), coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin could be potential treatment options.
=== Carcinogenesis === Deregulation of CK1δ contributes to tumorigenesis and tumor progression through deregulation of Wnt/β-catenin-, p53-, Hedgehog-, and Hippo-related signaling. CK1δ mRNA is overexpressed in various cancer entities, among them bladder cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, lung adenocarcinoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, hematopoietic malignancies and lymphoid neoplasms. Also decreased CK1δ mRNA expression levels have been observed in some cancer studies, like urinary bladder cancer, lung squamous cell carcinoma, stomach cancer, kidney cancer, esophageal cancer as well as head and neck cancer. Besides those, reduced CK1δ activity owing to the site N172D mutation of CK1δ decelerated mammary carcinoma progression, and prolonged mouse survival in a transgenic mouse model. The two CK1δ mutations, R324H and T67S identified in intestinal mucosa and in a colorectal tumor, respectively, exhibit increased carcinogenic potential.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.